Cargando…

Increased lipocalin-2 expression in pulmonary inflammation and fibrosis

INTRODUCTION: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic mechanisms are poorly understood, resulting in a lack of effective treatments. However, recurrent epithelial damage is considered critical for diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Galaris, Apostolos, Fanidis, Dionysios, Tsitoura, Eliza, Kanellopoulou, Paraskevi, Barbayianni, Ilianna, Ntatsoulis, Konstantinos, Touloumi, Katerina, Gramenoudi, Sofia, Karampitsakos, Theodoros, Tzouvelekis, Argyrios, Antoniou, Katerina, Aidinis, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513431/
https://www.ncbi.nlm.nih.gov/pubmed/37746070
http://dx.doi.org/10.3389/fmed.2023.1195501
_version_ 1785108569079676928
author Galaris, Apostolos
Fanidis, Dionysios
Tsitoura, Eliza
Kanellopoulou, Paraskevi
Barbayianni, Ilianna
Ntatsoulis, Konstantinos
Touloumi, Katerina
Gramenoudi, Sofia
Karampitsakos, Theodoros
Tzouvelekis, Argyrios
Antoniou, Katerina
Aidinis, Vassilis
author_facet Galaris, Apostolos
Fanidis, Dionysios
Tsitoura, Eliza
Kanellopoulou, Paraskevi
Barbayianni, Ilianna
Ntatsoulis, Konstantinos
Touloumi, Katerina
Gramenoudi, Sofia
Karampitsakos, Theodoros
Tzouvelekis, Argyrios
Antoniou, Katerina
Aidinis, Vassilis
author_sort Galaris, Apostolos
collection PubMed
description INTRODUCTION: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic mechanisms are poorly understood, resulting in a lack of effective treatments. However, recurrent epithelial damage is considered critical for disease initiation and perpetuation, via the secretion of soluble factors that amplify inflammation and lead to fibroblast activation and exuberant deposition of ECM components. Lipocalin-2 (LCN2) is a neutrophil gelatinase-associated lipocalin (NGAL) that has been suggested as a biomarker of kidney damage. LCN2 has been reported to modulate innate immunity, including the recruitment of neutrophils, and to protect against bacterial infections by sequestering iron. METHODS: In silico analysis of publicly available transcriptomic datasets; ELISAs on human IPF patients' bronchoalveolar lavage fluids (BALFs); bleomycin (BLM)-induced pulmonary inflammation and fibrosis and LPS-induced acute lung injury (ALI) in mice: pulmonary function tests, histology, Q-RT-PCR, western blot, and FACS analysis. RESULTS AND DISCUSSION: Increased LCN2 mRNA expression was detected in the lung tissue of IPF patients negatively correlating with respiratory functions, as also shown for BALF LCN2 protein levels in a cohort of IPF patients. Increased Lcn2 expression was also detected upon BLM-induced pulmonary inflammation and fibrosis, especially at the acute phase correlating with neutrophilic infiltration, as well as upon LPS-induced ALI, an animal model characterized by neutrophilic infiltration. Surprisingly, and non withstanding the limitations of the study and the observed trends, Lcn2(−/−) mice were found to still develop BLM- or LPS-induced pulmonary inflammation and fibrosis, thus questioning a major pathogenic role for Lcn2 in mice. However, LCN2 qualifies as a surrogate biomarker of pulmonary inflammation and a possible indicator of compromised pulmonary functions, urging for larger studies.
format Online
Article
Text
id pubmed-10513431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105134312023-09-22 Increased lipocalin-2 expression in pulmonary inflammation and fibrosis Galaris, Apostolos Fanidis, Dionysios Tsitoura, Eliza Kanellopoulou, Paraskevi Barbayianni, Ilianna Ntatsoulis, Konstantinos Touloumi, Katerina Gramenoudi, Sofia Karampitsakos, Theodoros Tzouvelekis, Argyrios Antoniou, Katerina Aidinis, Vassilis Front Med (Lausanne) Medicine INTRODUCTION: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic mechanisms are poorly understood, resulting in a lack of effective treatments. However, recurrent epithelial damage is considered critical for disease initiation and perpetuation, via the secretion of soluble factors that amplify inflammation and lead to fibroblast activation and exuberant deposition of ECM components. Lipocalin-2 (LCN2) is a neutrophil gelatinase-associated lipocalin (NGAL) that has been suggested as a biomarker of kidney damage. LCN2 has been reported to modulate innate immunity, including the recruitment of neutrophils, and to protect against bacterial infections by sequestering iron. METHODS: In silico analysis of publicly available transcriptomic datasets; ELISAs on human IPF patients' bronchoalveolar lavage fluids (BALFs); bleomycin (BLM)-induced pulmonary inflammation and fibrosis and LPS-induced acute lung injury (ALI) in mice: pulmonary function tests, histology, Q-RT-PCR, western blot, and FACS analysis. RESULTS AND DISCUSSION: Increased LCN2 mRNA expression was detected in the lung tissue of IPF patients negatively correlating with respiratory functions, as also shown for BALF LCN2 protein levels in a cohort of IPF patients. Increased Lcn2 expression was also detected upon BLM-induced pulmonary inflammation and fibrosis, especially at the acute phase correlating with neutrophilic infiltration, as well as upon LPS-induced ALI, an animal model characterized by neutrophilic infiltration. Surprisingly, and non withstanding the limitations of the study and the observed trends, Lcn2(−/−) mice were found to still develop BLM- or LPS-induced pulmonary inflammation and fibrosis, thus questioning a major pathogenic role for Lcn2 in mice. However, LCN2 qualifies as a surrogate biomarker of pulmonary inflammation and a possible indicator of compromised pulmonary functions, urging for larger studies. Frontiers Media S.A. 2023-09-07 /pmc/articles/PMC10513431/ /pubmed/37746070 http://dx.doi.org/10.3389/fmed.2023.1195501 Text en Copyright © 2023 Galaris, Fanidis, Tsitoura, Kanellopoulou, Barbayianni, Ntatsoulis, Touloumi, Gramenoudi, Karampitsakos, Tzouvelekis, Antoniou and Aidinis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Galaris, Apostolos
Fanidis, Dionysios
Tsitoura, Eliza
Kanellopoulou, Paraskevi
Barbayianni, Ilianna
Ntatsoulis, Konstantinos
Touloumi, Katerina
Gramenoudi, Sofia
Karampitsakos, Theodoros
Tzouvelekis, Argyrios
Antoniou, Katerina
Aidinis, Vassilis
Increased lipocalin-2 expression in pulmonary inflammation and fibrosis
title Increased lipocalin-2 expression in pulmonary inflammation and fibrosis
title_full Increased lipocalin-2 expression in pulmonary inflammation and fibrosis
title_fullStr Increased lipocalin-2 expression in pulmonary inflammation and fibrosis
title_full_unstemmed Increased lipocalin-2 expression in pulmonary inflammation and fibrosis
title_short Increased lipocalin-2 expression in pulmonary inflammation and fibrosis
title_sort increased lipocalin-2 expression in pulmonary inflammation and fibrosis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513431/
https://www.ncbi.nlm.nih.gov/pubmed/37746070
http://dx.doi.org/10.3389/fmed.2023.1195501
work_keys_str_mv AT galarisapostolos increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT fanidisdionysios increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT tsitouraeliza increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT kanellopoulouparaskevi increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT barbayianniilianna increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT ntatsouliskonstantinos increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT touloumikaterina increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT gramenoudisofia increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT karampitsakostheodoros increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT tzouvelekisargyrios increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT antonioukaterina increasedlipocalin2expressioninpulmonaryinflammationandfibrosis
AT aidinisvassilis increasedlipocalin2expressioninpulmonaryinflammationandfibrosis